About Relypsa (NASDAQ:RLYP)
Relypsa, Inc. is a United States-based biopharmaceutical company. The Company focuses on the discovery, development and commercialization of polymer-based medicines. The Company's technology platform includes a high-throughput chemistry process, enabling the Company to explore various potential polymer medicines for each disease it seeks to address. Its polymers are non-absorbed, meaning they act within the gastrointestinal tract and do not get absorbed into the bloodstream or other parts of the body. Its polymer technology may be able to address many health conditions in need of viable treatment options. Its VELTASSA (patiromer) for oral suspension is a commercialized medicine resulting from its polymer technology platform. VELTASSA is a potassium binder approved for the treatment of hyperkalemia. Available in powder form, VELTASSA is mixed with water and taken daily. VELTASSA's spherical beads bind to potassium in exchange for calcium, primarily in the colon.
Industry, Sector and Symbol
Trailing P/E RatioN/A
Forward P/E RatioN/A
Sales & Book Value
Price / SalesN/A
Price / CashN/A
Price / BookN/A
EPS (Most Recent Fiscal Year)N/A
Return on Equity-227.26%
Return on Assets-115.06%
Relypsa (NASDAQ:RLYP) Frequently Asked Questions
What is Relypsa's stock symbol?
Relypsa trades on the NASDAQ under the ticker symbol "RLYP."
How were Relypsa's earnings last quarter?
Relypsa Inc (NASDAQ:RLYP) posted its earnings results on Wednesday, May, 4th. The biotechnology company reported ($1.26) EPS for the quarter, topping the Zacks' consensus estimate of ($1.46) by $0.20. The biotechnology company had revenue of $12.40 million for the quarter, compared to the consensus estimate of $6.88 million. Relypsa had a negative return on equity of 227.26% and a negative net margin of 1,601.53%. During the same period in the previous year, the business earned ($0.78) earnings per share. View Relypsa's Earnings History.
Has Relypsa been receiving favorable news coverage?
Press coverage about RLYP stock has been trending positive this week, Accern Sentiment Analysis reports. The research group identifies positive and negative news coverage by monitoring more than twenty million news and blog sources in real-time. Accern ranks coverage of public companies on a scale of negative one to positive one, with scores closest to one being the most favorable. Relypsa earned a media sentiment score of 0.36 on Accern's scale. They also assigned headlines about the biotechnology company an impact score of 47.34 out of 100, meaning that recent news coverage is somewhat unlikely to have an impact on the stock's share price in the next few days.
How do I buy shares of Relypsa?
Shares of RLYP can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab.
What is Relypsa's stock price today?
One share of RLYP stock can currently be purchased for approximately $31.98.
How can I contact Relypsa?
Relypsa's mailing address is 100 Cardinal Way, REDWOOD CITY, CA 94063-4755, United States. The biotechnology company can be reached via phone at +1-650-4219500.
MarketBeat Community Rating for Relypsa (RLYP)MarketBeat's community ratings are surveys of what our community members think about Relypsa and other stocks. Vote "Outperform" if you believe RLYP will outperform the S&P 500 over the long term. Vote "Underperform" if you believe RLYP will underperform the S&P 500 over the long term. You may vote once every thirty days.
Relypsa (NASDAQ:RLYP) Earnings History and Estimates Chart
Relypsa (NASDAQ RLYP) Earnings History by Quarter
(Earnings results data provided by Zacks Investment Research)
|Date||Quarter||Consensus Estimate||Actual EPS||Revenue Estimate||Actual Revenue||Release Link||Conference Call||Details|
|8/4/2016||Q2 2016||($1.53)||($1.87)||$4.47 million||$5.22 million||View||N/A|
|5/4/2016||Q1||($1.46)||($1.26)||$6.88 million||$12.40 million||View||Listen|
|2/24/2016||Q415||($1.35)||($1.40)||$7.37 million||$11.96 million||View||Listen|
|11/4/2015||Q3||($0.89)||($1.24)||$6.67 million||$6.50 million||View||N/A|
Relypsa (NASDAQ:RLYP) Dividend History by Quarter
(Data available from 1/1/2013 forward)
|Announced||Period||Amount||Yield||Ex-Dividend Date||Record Date||Payable Date|
Relypsa (NASDAQ RLYP) Insider Trading and Institutional Ownership History
Relypsa (NASDAQ RLYP) Insider Trading History
(Data available from 1/1/2013 forward)
|Transaction Date||Insider Name||Title||Buy/Sell||Number of Shares||Average Share Price||Total Transaction||Shares Held After Transaction||Details|
|8/17/2016||James D Dondero||Major Shareholder||Buy||500||$31.92||$15,960.00|| |
|8/16/2016||Monte Montgomery||Insider||Sell||510||$31.92||$16,279.20|| |
|8/11/2016||James D Dondero||Major Shareholder||Sell||37,000||$31.96||$1,182,520.00|| |
|7/25/2016||Orbimed Advisors Llc||Major Shareholder||Sell||4,043,600||$32.00||$129,395,200.00|| |
|6/7/2016||David W J Mcgirr||Director||Sell||1,013||$19.34||$19,591.42||2,729|| |
|3/16/2016||Kristine M Ball||CFO||Buy||7,000||$12.15||$85,050.00||28,290|| |
|3/15/2016||Thomas J Schuetz||Director||Buy||30,000||$13.39||$401,700.00||33,962|| |
|12/31/2015||Wilhelm Stahl||SVP||Sell||20,000||$28.53||$570,600.00||14,853|| |
|12/23/2015||Orbimed Advisors Llc||Major Shareholder||Sell||500,000||$27.18||$13,590,000.00|| |
|12/9/2015||Lance Berman||SVP||Sell||750||$29.50||$22,125.00||21,290|| |
|12/7/2015||John A. Orwin||CEO||Sell||15,000||$28.28||$424,200.00||54,375|| |
|12/7/2015||Lance Berman||SVP||Sell||30,000||$29.78||$893,400.00||21,290|| |
|12/4/2015||John A. Orwin||CEO||Sell||40,000||$25.00||$1,000,000.00||59,375|| |
|10/22/2015||Orbimed Advisors Llc||Major Shareholder||Buy||500,000||$12.56||$6,280,000.00|| |
|8/17/2015||John A Orwin||CEO||Sell||5,000||$24.84||$124,200.00|| |
|8/17/2015||Lance Berman||SVP||Sell||710||$24.77||$17,586.70||15,040|| |
|8/17/2015||Ronald A Krasnow||Insider||Sell||522||$24.75||$12,919.50||10,478|| |
|6/11/2015||Thomas J Schuetz||Director||Sell||1,000||$34.57||$34,570.00|| |
|6/1/2015||John A Orwin||CEO||Sell||33,555||$36.42||$1,222,073.10|| |
|5/18/2015||Orbimed Advisors Llc||Major Shareholder||Sell||1,457,551||$34.13||$49,746,215.63|| |
|5/11/2015||Klaus R Dr Veitinger||Director||Sell||5,834||$36.06||$210,374.04|| |
|4/10/2015||Klaus R Dr Veitinger||Director||Sell||5,832||$35.35||$206,161.20|| |
|3/5/2015||Kristine M Ball||CFO||Sell||3,519||$40.68||$143,152.92|| |
|2/27/2015||Ronald A Krasnow||Insider||Sell||10,348||$39.00||$403,572.00|| |
|2/24/2015||Lance Berman||SVP||Sell||5,000||$38.19||$190,950.00|| |
|2/24/2015||Ronald A Krasnow||Insider||Sell||10,000||$39.00||$390,000.00|| |
|2/10/2015||Klaus R Dr Veitinger||Director||Sell||5,834||$32.12||$187,388.08|| |
|1/21/2015||Claire Lockey||Insider||Sell||5,000||$35.00||$175,000.00|| |
|1/21/2015||Kristine M Ball||CFO||Sell||3,000||$36.00||$108,000.00|| |
|1/14/2015||Ronald A Krasnow||Insider||Sell||5,000||$33.58||$167,900.00|| |
|1/12/2015||Klaus R Dr Veitinger||Director||Sell||5,834||$32.33||$188,613.22|| |
|12/12/2014||Klaus R Dr Veitinger||Director||Sell||14,169||$32.16||$455,675.04|| |
|12/9/2014||5Am Partners Iii, Llc||Major Shareholder||Sell||589,637||$30.04||$17,712,695.48|| |
|12/9/2014||Claire Lockey||Insider||Sell||8,000||$30.00||$240,000.00|| |
|11/25/2014||Lance Berman||SVP||Sell||30,000||$25.00||$750,000.00|| |
|10/10/2014||Klaus R Dr Veitinger||Director||Sell||2,500||$19.34||$48,350.00|| |
|9/24/2014||Lance Berman||SVP||Sell||5,000||$22.00||$110,000.00|| |
|9/17/2014||Orbimed Advisors Llc||Major Shareholder||Sell||94,000||$25.27||$2,375,380.00|| |
|9/16/2014||5Am Partners Ii, Llc||Major Shareholder||Sell||612,540||$26.03||$15,944,416.20|| |
|9/10/2014||Klaus R Dr Veitinger||Director||Sell||4,167||$23.00||$95,841.00|| |
|8/29/2014||Wilhelm Stahl||SVP||Sell||15,785||$25.29||$399,202.65|| |
|8/26/2014||5Am Partners Ii, Llc||Major Shareholder||Sell||433,000||$26.51||$11,478,830.00|| |
|8/25/2014||Lance Berman||SVP||Sell||20,000||$25.89||$517,800.00|| |
|8/11/2014||Klaus R Dr Veitinger||Director||Sell||4,167||$27.73||$115,550.91|| |
|7/24/2014||Lance Berman||SVP||Sell||45,000||$23.92||$1,076,400.00|| |
|7/10/2014||Klaus R Dr Veitinger||Director||Sell||4,167||$23.12||$96,341.04|| |
|11/20/2013||5Am Partners Iii, Llc||Major Shareholder||Buy||372,692||$11.00||$4,099,612.00|| |
|11/20/2013||John A Orwin||CEO||Buy||15,000||$11.00||$165,000.00|| |
|11/20/2013||Leaf Ventures I L.P. New||Insider||Buy||185,978||$11.00||$2,045,758.00|| |
|11/20/2013||Scott M Rocklage||Director||Buy||363,328||$11.00||$3,996,608.00|| |
Relypsa (NASDAQ RLYP) News Headlines
Relypsa (NASDAQ:RLYP) SEC Filings
This page is loading this company's SEC Filings. Please wait...
Relypsa (NASDAQ:RLYP) Income Statement, Balance Sheet and Cash Flow Statement
Relypsa (NASDAQ RLYP) Stock Chart for Thursday, April, 26, 2018